Eisai hires Celgene exec as SVP for Americas Commercial oncology unit

Eisai Inc. has named a new senior vice president of its Americas Commercial, Oncology Business Group.

The Tokyo-based company’s U.S. pharmaceutical subsidiary is headquartered in Woodcliff Lake.

Michael Amoroso will lead the team in creating and driving commercial strategies for the company’s approved products, pipeline assets and late-stage compounds approaching the commercialization stage.

He also will be a member of the Eisai Inc. Americas executive committee.

Amoroso has more than 20 years of experience in oncology and other therapeutic areas, and spent the last six years at Celgene, where he served in a variety of marketing roles.

“Michael has been tremendously successful in launching oncology brands, developing and collaborating on disease awareness initiatives, repositioning global brand plans, crafting development plans with (research and development) and medical colleagues, and leading large cross-functional teams in working together to deliver high-quality value to customers and patients,” Esai Chief Operating Officer Shaji Procida said. “We are confident that his extensive experience and proven leadership will help drive the growth of Eisai’s oncology business in the Americas.”

As Celgene’s commercial head of global markets for CAR-T programs, he developed the company’s global organizational model to commercialize cell therapies involving specialized manufacturing and customer services for lymphoma and myeloma patients.

Amoroso received his Master of Business Administration from New York University’s Stern School of Business. And earned his Bachelor of Arts degree from Rider University in biological sciences.